Shots:

• The designation is based on efficacy & safety results from the P-II FOENIX-CCA2 study involves assessing futibatinib (TAS-120) in patients with advanced cholangiocarcinoma. The findings will be presented at AACR 2021
• The preliminary clinical evidence showed improvement on at least one clinical EPs over available therapy
• Futibatinib (TAS-120- PO) is a covalently-binding FGFR inhibitor for the treatment of patients with previously treated LA/m-cholangiocarcinoma harboring FGFR2 gene rearrangements- including gene fusions

  Ref: PRNewswire | Image: PRNewswire